{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=43", "query": { "intervention": "Placebo (Cohort 3)", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 1069, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T23:48:49.350Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06013995", "title": "A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus" ], "interventions": [ { "name": "BMS-986326", "type": "DRUG" }, { "name": "Placebo for BMS-986326", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 45, "start_date": "2023-09-21", "completion_date": "2026-04-14", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 7, "location_summary": "San Diego, California • Clearwater, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06013995" }, { "nct_id": "NCT07216001", "title": "Role of Omega-DEK in Childhood Apraxia of Speech", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Apraxia of Speech", "Verbal Apraxia", "Autism" ], "interventions": [ { "name": "Omega-DEK", "type": "DRUG" }, { "name": "L-carnitine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Claudia R. Morris", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "36 Months", "maximum_age": "6 Years", "sex": "ALL", "summary": "36 Months to 6 Years" }, "enrollment_count": 34, "start_date": "2026-11", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216001" }, { "nct_id": "NCT02593851", "title": "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus Infections", "Virus Diseases" ], "interventions": [ { "name": "JNJ-53718678", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Sciences Ireland UC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "24 Months", "sex": "ALL", "summary": "1 Month to 24 Months" }, "enrollment_count": 45, "start_date": "2015-12-04", "completion_date": "2017-11-10", "has_results": false, "last_update_posted_date": "2019-12-06", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 1, "location_summary": "Kirksville, Missouri", "locations": [ { "city": "Kirksville", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02593851" }, { "nct_id": "NCT02211261", "title": "A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "PF-06293620", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 84, "start_date": "2014-09-15", "completion_date": "2017-01-27", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 7, "location_summary": "Chula Vista, California • DeLand, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02211261" }, { "nct_id": "NCT06469164", "title": "A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bacterial Vaginosis" ], "interventions": [ { "name": "BNT331", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 102, "start_date": "2024-07-01", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Marrero, Louisiana • Metairie, Louisiana + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Marrero", "state": "Louisiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06469164" }, { "nct_id": "NCT04313400", "title": "Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "1.1% w/w AMTX-100 CF-part1", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "1.1% w/w AMTX-100 CF3-part2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amytrx Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2020-03-10", "completion_date": "2024-01-02", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 11, "location_summary": "Cerritos, California • Encino, California • Long Beach, California + 8 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04313400" }, { "nct_id": "NCT07703514", "title": "Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "cH15/3", "type": "BIOLOGICAL" }, { "name": "cH4/3", "type": "BIOLOGICAL" }, { "name": "cH5/1N1", "type": "BIOLOGICAL" }, { "name": "cH8/1N1", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 60, "start_date": "2026-09-18", "completion_date": "2027-04-12", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07703514" }, { "nct_id": "NCT03370133", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis", "Moderate to Severe Chronic Plaque Psoriasis", "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2017-12-06", "completion_date": "2019-12-13", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370133" }, { "nct_id": "NCT03410992", "title": "A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis", "Moderate to Severe Chronic Plaque Psoriasis", "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 435, "start_date": "2018-02-05", "completion_date": "2020-01-07", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 20, "location_summary": "San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03410992" }, { "nct_id": "NCT03844191", "title": "A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronary Disease" ], "interventions": [ { "name": "RUC-4 Compound", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CeleCor Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2019-02-18", "completion_date": "2019-12-01", "has_results": false, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-10-17T23:48:49.350Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03844191" } ] }